Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...
Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...
If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...
New research finds older women achieve the best results with weight loss injections – thanks to consistent tracking and ...
A nutritionist shared 10 foods she stopped eating while losing 20 kg, including packed yoghurt, cakes, and ice cream. Check out her full list.
The singer reflected on being ‘so broken and dark’ a year ago.